Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.
Treatment of adult relapsed or refractory acute lymphoblastic leukemia with inotuzumab ozogamicin was associated with increased hepatotoxicity, especially after follow-up hematopoietic stem cell transplantation.
The FDA placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma.
ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.
The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.
Patients with high-risk diffuse large B-cell lymphoma had a reduced risk of treatment failure, but no survival improvement, with an abbreviated course of rituximab-dose-dense chemotherapy plus high-dose chemotherapy and transplant compared with a full course of chemotherapy.
Treatment with the combination of daratumumab plus pomalidomide/dexamethasone resulted in rapid, deep, and sustained responses with no new safety signals in patients with heavily treated multiple myeloma.
Calcium and vitamin D supplementation had a protective effect against hematologic malignancies, according to a post-hoc analysis of data from the Women’s Health Initiative Calcium/Vitamin D study.
There was no significant survival difference in newly diagnosed acute myeloid leukemia patients given induction therapy with idarubicin vs high-dose daunorubicin.
Adult patients with early thymic precursor (ETP) acute lymphoblastic leukemia (ALL), a subgroup of T-cell ALL, could benefit from the use of response-based risk stratification and therapy intensification similar to that used in pediatric patients with ETP-ALL.